ArticleInternational journal of clinical pharmacy2024

Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database.

Dan Zou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.